{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:05:28Z","timestamp":1779447928936,"version":"3.53.1"},"reference-count":35,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Retinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV), often require repeated intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. Although ranibizumab is well established, long-term affordability remains challenging. Objective: To compare the functional, anatomical, treatment-burden, and safety outcomes of biosimilar ranibizumab (Ranieyes) and innovator ranibizumab (Lucentis\/Accentrix) in routine clinical practice. Methods: This multicenter retrospective comparative study included 4997 eyes from 3577 patients treated across five tertiary eye-care centers in India. The biosimilar group comprised 2543 eyes from 1812 patients (10,893 injections), and the innovator group comprised 2454 eyes from 1765 patients (10,136 injections). Eligible indications were nAMD, DME, BRVO, CRVO, mCNV, and an exploratory miscellaneous preoperative adjunct subgroup. BCVA (logMAR), central subfield thickness (CST; \u00b5m), injection burden, and ocular\/systemic adverse events were assessed over 24 months. Results: Both groups showed early improvement in BCVA and CST across the major disease categories, followed by long-term stabilization. Between-group differences were generally small, not sustained over follow-up, and of limited clinical magnitude. Serious ocular and systemic adverse events were rare in both groups, and no new safety signal emerged. Conclusions: In this large real-world cohort, the biosimilar ranibizumab Ranieyes showed outcomes broadly comparable to innovator ranibizumab across the major retinal disease subgroups, although these findings should be interpreted as observational comparative evidence rather than formal proof of equivalence.<\/jats:p>","DOI":"10.3390\/ph19050747","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:07:47Z","timestamp":1779444467000},"page":"747","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis\/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study)"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-7882","authenticated-orcid":false,"given":"Debdulal","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Disha Eye Hospitals, Kolkata 700029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar Kanti","family":"Sinha","sequence":"additional","affiliation":[{"name":"Disha Eye Hospitals, Kolkata 700029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Sinha","sequence":"additional","affiliation":[{"name":"Nethralayam Superspeciality Eye Hospital, Kolkata 700073, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak Kanti","family":"Biswas","sequence":"additional","affiliation":[{"name":"Nethralayam Superspeciality Eye Hospital, Kolkata 700073, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Das","sequence":"additional","affiliation":[{"name":"Disha Eye Hospitals, Kolkata 700029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Maiti","sequence":"additional","affiliation":[{"name":"Global Eye Hospital, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranabir","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Disha Eye Hospitals, Kolkata 700029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouvick","family":"Dan","sequence":"additional","affiliation":[{"name":"Disha Eye Hospitals, Kolkata 700029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Rungta","sequence":"additional","affiliation":[{"name":"Disha Eye Hospitals, Kolkata 700029, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibashis","family":"Das","sequence":"additional","affiliation":[{"name":"Sankara Jyoti Eye Institute, Kolkata 700060, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.62.14.26","article-title":"Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture","volume":"62","author":"Campochiaro","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40123-021-00362-1","article-title":"Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab\u2122 (World\u2019s First Biosimilar Ranibizumab): A Comprehensive Review","volume":"10","author":"Sharma","year":"2021","journal-title":"Ophthalmol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.36469\/jheor.2024.93022","article-title":"The Association of Retinal Disease with Vision Impairment and Functional Status in Medicare Patients","volume":"11","author":"Garmo","year":"2024","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41433-022-02075-6","article-title":"Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion","volume":"37","author":"Bhandari","year":"2023","journal-title":"Eye"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.2147\/OPTH.S479816","article-title":"Evolution of Workload Associated with Anti-VEGF Treatments for AMD, DME, RVO and mCNV in Hospital District of Southwest Finland","volume":"18","author":"Viita","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hang, A., Feldman, S., Amin, A.P., Ochoa, J.A.R., and Park, S.S. (2023). Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals, 16.","DOI":"10.3390\/ph16081140"},{"key":"ref_7","first-page":"592","article-title":"Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications","volume":"9","author":"Lantry","year":"2007","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00417-019-04362-7","article-title":"Repeated intravitreal injections of antivascular endothelial growth factors and risk of intraocular pressure medication use","volume":"257","author":"Cui","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bas, T.G. (2025). Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060908"},{"key":"ref_10","first-page":"411","article-title":"Managing high-priced biologic agents: Challenges and potential solutions","volume":"27","author":"Li","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41433-019-0745-z","article-title":"Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: Real-world data","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/DDDT.S457303","article-title":"Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?","volume":"18","author":"Chatzimichail","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.2147\/OPTH.S549744","article-title":"Biosimilar Versus Innovator Ranibizumab in CNVM: Comparative Real-World Outcomes\u2014The BRIM Study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lee, S.Y., and Hwang, D.D.-J. (2025). Short-Term Effects of Intravitreal Ranibizumab Biosimilar Injections in Patients with Neovascular Age-Related Macular Degeneration on Retinal Nerve Fiber Layer Thickness. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228225"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamaophthalmol.2022.5543","article-title":"Biosimilar Ranibizumab and Innovator Ranibizumab\u2014Immunogenicity Assessment and Its Impact on Safety and Efficacy","volume":"141","author":"Sharma","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/eye.2012.32","article-title":"Management of retinal vascular diseases: A patient-centric approach","volume":"26","author":"Brand","year":"2012","journal-title":"Eye"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Daien, V., Eldem, B.M., Talks, J.S., Korobelnik, J.F., Mitchell, P., Finger, R.P., Sakamoto, T., Wong, T.Y., Evuarherhe, O., and Carter, G. (2019). Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy\u2014A systematic approach to identify and characterize data sources. BMC Ophthalmol., 19.","DOI":"10.1186\/s12886-019-1208-9"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/COPD.S244942","article-title":"Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy","volume":"15","author":"Tashkin","year":"2020","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/oncolo\/oyab071","article-title":"Blurring the Lines of Design: Prospective Observational Cohorts and Pragmatic Clinical Trials Characterizing Treatment Effects in Routine Cancer Care","volume":"27","author":"Rivera","year":"2022","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/2474126420906395","article-title":"Current Best Clinical Practices-Management of Retinal Vein Occlusion","volume":"4","author":"Modi","year":"2020","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijo.IJO_2516_20","article-title":"Clinical efficacy and safety of Razumab\u00ae (CESAR) study: Our experience with the world\u2019s first biosimilar Ranibizumab","volume":"69","author":"Verma","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00417-023-06271-2","article-title":"Treatment of myopic choroidal neovascularization: A network meta-analysis and review","volume":"262","author":"Glachs","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_23","first-page":"733","article-title":"Current and emerging treatment options for myopic choroidal neovascularization","volume":"9","author":"Chebil","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1208\/s12248-016-9882-5","article-title":"Analytical Similarity Assessment in Biosimilar Studies","volume":"18","author":"Chow","year":"2016","journal-title":"AAPS J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Niazi, S.K. (2022). Molecular Biosimilarity\u2014An AI-Driven Paradigm Shift. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202208.0194.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","article-title":"Biosimilars for Retinal Diseases: An Update","volume":"224","author":"Sharma","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6641008","DOI":"10.1155\/2021\/6641008","article-title":"Real-World Outcomes in Patients with Branch Retinal Vein Occlusion- (BRVO-) Related Macular Edema Treated with Anti-VEGF Injections Alone versus Anti-VEGF Injections Combined with Focal Laser","volume":"2021","author":"Thomley","year":"2021","journal-title":"J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e002334","DOI":"10.1136\/bmjophth-2025-002334","article-title":"Tracking real-world persistence and adherence to anti-VEGF intravitreal therapy with prefilled syringes: A German prescription sales analysis","volume":"10","author":"Brunner","year":"2025","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4103\/ijo.IJO_1538_20","article-title":"The economic burden of diabetic retinopathy care at a tertiary eye care center in South India","volume":"69","author":"Orji","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab Treatment in Treatment-Naive Neovascular Age-Related Macular Degeneration: Results from Luminous, a Global Real-World Study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme","volume":"97","author":"Holz","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_32","first-page":"24741264251322213","article-title":"Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study","volume":"27","author":"Sharma","year":"2025","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/OPTH.S515479","article-title":"CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases\u2014The CRsIBS Study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.4103\/ijo.IJO_430_19","article-title":"Ophthalmic biosimilars: Lessons from India","volume":"67","author":"Sharma","year":"2019","journal-title":"Indian J. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1038\/s41433-024-03284-x","article-title":"Anti-VEGF Biosimilars for Retinal Diseases Survey 2023-India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)","volume":"38","author":"Sharma","year":"2024","journal-title":"Eye"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/747\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:15:38Z","timestamp":1779444938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ph19050747"],"URL":"https:\/\/doi.org\/10.3390\/ph19050747","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}